Mostrar el registro sencillo del ítem
dc.contributor.author
Pacienza, Natalia
dc.contributor.author
Santa Cruz, Diego Mario
dc.contributor.author
Malvicini, Ricardo
dc.contributor.author
Robledo, Oscar
dc.contributor.author
Lemus Larralde, Gastón
dc.contributor.author
Bertolotti, Alejandro Mario
dc.contributor.author
Marcos, Martín
dc.contributor.author
Yannarelli, Gustavo Gabriel
dc.date.available
2021-01-04T17:44:48Z
dc.date.issued
2019-08
dc.identifier.citation
Pacienza, Natalia; Santa Cruz, Diego Mario; Malvicini, Ricardo; Robledo, Oscar; Lemus Larralde, Gastón; et al.; Mesenchymal stem cell therapy facilitates donor lung preservation by reducing oxidative damage during ischemia; Hindawi Publishing Corporation; Stem Cells International; 2019; 8-2019; 1-14
dc.identifier.issn
1687-9678
dc.identifier.uri
http://hdl.handle.net/11336/121400
dc.description.abstract
Lung transplantation is a lifesaving therapy for people living with severe, life-threatening lung disease. The high mortality rate among patients awaiting transplantation is mainly due to the low percentage of lungs that are deemed acceptable for implantation. Thus, the current shortage of lung donors may be significantly reduced by implementing different therapeutic strategies which facilitate both organ preservation and recovery. Here, we studied whether the anti-inflammatory effect of human umbilical cord-derived mesenchymal stem cells (HUCPVCs) increases lung availability by improving organ preservation. We developed a lung preservation rat model that mimics the different stages by which donor organs must undergo before implantation. The therapeutic schema was as follows: cardiac arrest, warm ischemia (2h at room temperature), cold ischemia (1.5h at 4°C, with Perfadex), and normothermic lung perfusion with ventilation (Steen solution, 1h). After 1h of warm ischemia, HUCPVCs (1x106 cells) or vehicle were infused via the pulmonary artery. Physiologic data (pressure-volume curves) were acquired right after the cardiac arrest and at the end of the perfusion. Interestingly, although lung edema did not change among groups, lung compliance dropped a 34% in the HUCPVCs-treated group, while the vehicle group showed a stronger reduction (69%, p<0.0001). Histologic assessment demonstrated less overall inflammation in HUCPVCs-treated lungs. In addition, MPO activity, a neutrophil marker, was reduced by 41% compared with vehicle (p<0.01). MSCs therapy significantly decreased tissue oxidative damage by controlling reactive oxygen species production. Accordingly, catalase and superoxide dismutase enzyme activities remained at baseline levels. In conclusion, these results demonstrate that the anti-inflammatory effect of MSCs protects donor lungs against ischemic injury and postulate MSCs therapy as a novel tool for organ preservation.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Hindawi Publishing Corporation
dc.rights
info:eu-repo/semantics/openAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.subject
MESENCHYMAL STEM CELL
dc.subject
ORGAN PRESERVATION
dc.subject
LUNG TRANSPLANTATION
dc.subject
CELL THERAPY
dc.subject
INFLAMMATION
dc.subject
OXIDATIVE STRESS
dc.subject.classification
Tecnologías que involucran la manipulación de células, tejidos, órganos o todo el organismo
dc.subject.classification
Biotecnología de la Salud
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
dc.title
Mesenchymal stem cell therapy facilitates donor lung preservation by reducing oxidative damage during ischemia
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2020-12-11T14:56:43Z
dc.journal.volume
2019
dc.journal.pagination
1-14
dc.journal.pais
Estados Unidos
dc.description.fil
Fil: Pacienza, Natalia. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Medicina Traslacional, Trasplante y Bioingeniería. Fundación Favaloro. Instituto de Medicina Traslacional, Trasplante y Bioingeniería; Argentina
dc.description.fil
Fil: Santa Cruz, Diego Mario. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Medicina Traslacional, Trasplante y Bioingeniería. Fundación Favaloro. Instituto de Medicina Traslacional, Trasplante y Bioingeniería; Argentina
dc.description.fil
Fil: Malvicini, Ricardo. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Medicina Traslacional, Trasplante y Bioingeniería. Fundación Favaloro. Instituto de Medicina Traslacional, Trasplante y Bioingeniería; Argentina
dc.description.fil
Fil: Robledo, Oscar. Universidad Nacional de La Plata. Facultad de Ciencias Veterinarias; Argentina
dc.description.fil
Fil: Lemus Larralde, Gastón. Universidad Nacional de La Plata. Facultad de Ciencias Veterinarias; Argentina
dc.description.fil
Fil: Bertolotti, Alejandro Mario. Fundación Favaloro; Argentina
dc.description.fil
Fil: Marcos, Martín. Universidad Nacional de La Plata. Facultad de Ciencias Veterinarias; Argentina
dc.description.fil
Fil: Yannarelli, Gustavo Gabriel. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Medicina Traslacional, Trasplante y Bioingeniería. Fundación Favaloro. Instituto de Medicina Traslacional, Trasplante y Bioingeniería; Argentina
dc.journal.title
Stem Cells International
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.hindawi.com/journals/sci/
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1155/2019/8089215
Archivos asociados